35 results about "Astragaloside II" patented technology

The invention discloses a strain of bacillus licheniformis and its application, belonging to the technical field of biological fermentation and biological transformation. The bacillus licheniformis LZZT‑002 disclosed by the invention has xylanase activity and cellulase activity, and using it for fermentation and conversion of astragalus extract can increase the yield of astragalus polysaccharide, astragalus saponin and derivatives thereof. The fermented astragalus feed additive prepared by fermenting astragalus with bacterial strain LZZT-002 of the present invention is a high-efficiency microbial bacterial agent that integrates probiotics and active ingredients of traditional Chinese medicines, has the characteristics of environmental protection, excellent performance, etc., and has good economic and social benefits.

The invention discloses a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, which comprises 35.0-75% of astragalus root saponin extract containing total saponins 70-98%, 0.5-5.0% of tanshinone extract containing tanshinone 55-85%, 15.0-55.0% of total savianolic acid extract containing total savianolic acid 70-98%, 2.5-15.0% of pseudo-ginseng leaf glycosides extract containing total saponins 80-90%, and natural borneol or rosewood oil 2.5-15.0%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of tanshinone, total savianolic acid or pseudo-ginseng leaf glycosides, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.

The invention discloses a pharmaceutical composition for treating hyperlipidemia and atherosclerosis. The pharmaceutical composition comprises: active components, the active components are puerarin, daidzin, genistin, soybean Aglycone, Actascoisoflavone Glucoside, Astragaloside II, Astragaloside IV, Formononetin, Mulberry A, Moranginin, Scopoletin, Sanggenone C, 1-deoxynojirimycin, Pueraria polysaccharide , a combination of two or more of Astragalus polysaccharide and Morus alba polysaccharide; and a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention can reduce the fat plaque area in the aorta of apoE- / -transgenic mice of atherosclerosis model, has the effect of regulating hyperlipidemia in mice, and can treat hyperlipidemia and atherosclerosis.

The invention discloses an astragalus extract and a preparation method thereof and application. Astragalus is smashed, water is added to soak the astragalus, ultrasonic extraction and filtration are performed, and filtrate is taken; the filtrate is concentrated, ethanol is added to perform extraction three times, and the ethanol extraction concentrations are sequentially 50-55%, 65-75% and 90% or above. The filtrate filtered through ethanol extraction for the third time and filter residue are treated respectively, the filtrate undergoes impurity removal, and astragaloside extracting solution is obtained; the filter residue undergoes impurity removal to obtain astragalus polysaccharide extracting liquid; and the astragaloside extracting solution and the astragalus polysaccharide extracting liquid are combined to obtain the astragalus extract. The astragalus extract retains active ingredients of saponin and polysaccharide in astragalus and can be directly used for preparing medicines for treating myocarditis or is combined with other medicines to prepare the medicines for treating myocarditis.

The invention relates to technical fields of traditional Chinese medicine active ingredient extraction and application. The astragaloside II has obvious inhibition effect on proliferation of two human liver cancer cells, namely BEL-7402 and BEL-7402 / 5-FU under the condition of different concentrations, and can be administrated with other medicines simultaneously or sequentially to achieve the anti-tumor effect. The invention provides an anti-tumor medicine with definite response relationship and corroborant structural components, lays a foundation for developing new clinical anti-tumor medicines, provides a medicine for reversing multidrug resistance to achieve the anti-tumor effect, and provides a new scheme for solving the problem of multidrug resistance of chemotherapeutics.